Kidney International Reports

Kidney International Reports is the online-only, open-access sister journal of Kidney International, published by Elsevier for the International Society of Nephrology and devoted to clinical research on kidney disease, with a 2025 Journal Impact Factor of 6.2.《国际肾脏报告》是（Kidney International）的纯在线开放获取姊妹刊，由（Elsevier）代表国际肾脏病学会出版，专注肾脏疾病的临床研究，2025 年期刊影响因子为 6.2。

Scope

• The journal publishes original clinical and selected translational work on the pathogenesis, evaluation and management of acute kidney injury and chronic kidney disease.期刊发表急性肾损伤与慢性肾脏病在发病机制、评估和管理方面的原创临床研究，并收录少量转化医学论文。
• End-stage kidney disease, kidney transplantation, acid-base and electrolyte disorders, and hypertension sit within the same core remit.终末期肾病、肾移植、酸碱与电解质紊乱以及高血压同属核心报道范围。
• Clinical trials, epidemiology, systematic reviews with meta-analysis and outcomes research are named as priority submissions.临床试验、流行病学、含荟萃分析的系统综述与结局研究被列为优先投稿类型。
• The journal also disseminates national and regional clinical practice guidelines and reports of consensus conferences.期刊还承担国家与地区临床实践指南及共识会议报告的传播职能。
• Article categories include full-length articles, research letters, case reports, editorials, narrative reviews and commentaries.栏目包括全文、研究快报、病例报告、社论、叙述性综述与评论。
• Work on education, socio-medical sciences, public health and pharmacology is welcome when it bears directly on nephrology and patient care.与肾脏病学和患者诊疗直接相关的教育、社会医学、公共卫生与药理学研究同样受欢迎。
• Research from low- and middle-income countries is actively encouraged, with fee support for authors in economically distressed regions.期刊积极鼓励中低收入国家的研究，并为经济困难地区的作者提供费用支持。

History

• The title was launched in 2016 as an exclusively online, open-access companion to Kidney International, with Jai Radhakrishnan as founding editor and Radha McLean as executive editor.本刊于 2016 年创刊，是（Kidney International）的纯在线开放获取姊妹刊，Jai Radhakrishnan 任首任主编，Radha McLean 任执行编辑。
• Its birth followed the expiry in 2015 of the society's long-running contract with Nature Publishing Group and the award of a ten-year publishing contract to Elsevier.其创办背景是学会与（Nature Publishing Group）的长期合同于 2015 年到期，随后将十年出版合同授予（Elsevier）。
• The title was announced as a bimonthly at launch and now appears twelve times a year, reaching volume 11 in 2026.创刊时宣布为双月刊，现每年出版 12 期，2026 年出至第 11 卷。
• Publication is financed by an article publishing charge of USD 3,100, discounted for society members and waived for authors covered by WHO and HINARI criteria.出版经费来自 3,100 美元的论文处理费，学会会员享受折扣，符合世界卫生组织与（HINARI）标准的作者可获减免。
• The 2025 Journal Impact Factor is 6.2 and the CiteScore is 7.0, placing the journal 15th among 134 titles in urology and nephrology.2025 年期刊影响因子为 6.2，CiteScore 为 7.0，在泌尿学与肾脏病学类 134 种期刊中位列第 15。
• It is indexed in SCIE, Scopus, PubMed Central and DOAJ, and the median interval from acceptance to online publication is nine days.期刊被 SCIE、Scopus、PMC 与 DOAJ 收录，从录用到在线发表的中位时间为 9 天。

Editors

• Jai Radhakrishnan, MD, of Columbia University Vagelos College of Physicians and Surgeons in New York has led the journal since its foundation.主编 Jai Radhakrishnan 任职于纽约的（Columbia University Vagelos College of Physicians and Surgeons），自创刊起领导本刊。
• Radha McLean is executive managing editor and Meghann Knowles is managing editor, both working from the New York editorial office.Radha McLean 任执行管理编辑，Meghann Knowles 任管理编辑，两人均在纽约编辑部工作。
• The board is predominantly North American, listing 63 members from the United States and 17 from Australia, with further editors in Spain, India, South Africa, Brazil, Romania and the Philippines.编委会以北美为主体，美国列名 63 人、澳大利亚 17 人，另有西班牙、印度、南非、巴西、罗马尼亚与菲律宾的编委。
• A standing panel of statistical reviewers assesses the design and analysis of trials and observational studies before acceptance.期刊设常设统计审稿人小组，在录用前评估试验与观察性研究的设计和统计分析。
• Submissions are screened by an editor and, if suitable, sent to two independent referees under single anonymized review, with the editor-in-chief issuing the final decision.稿件先经编辑筛选，适宜者送两位独立审稿人进行单盲评审，最终决定由主编作出。
• Original articles receive a graphical abstract produced in house by the journal's own nephrologists and designers rather than supplied by authors.原创论文的图形摘要由期刊内部的肾脏病学专家与设计师制作，而非由作者提供。
• All clinical trials must be registered publicly before submission, and reports must follow CONSORT, STROBE or PRISMA checklists together with a mandatory data sharing statement.所有临床试验须在投稿前完成公共注册，报告须遵循（CONSORT）、（STROBE）或（PRISMA）清单，并附强制性的数据共享声明。